Carregando...
The SGLT2 Inhibitor Empagliflozin Ameliorates the Inflammatory Profile in Type 2 Diabetic Patients and Promotes an Antioxidant Response in Leukocytes
Sodium–glucose co-transporter 2 inhibitors (iSGLT2) have been linked to a considerable reduction in cardiovascular risk in patients with type 2 diabetes (T2D), but the precise molecular mechanisms are still elusive. We aimed to evaluate the effects of the iSGLT2 empagliflozin on systemic inflammatio...
Na minha lista:
| Publicado no: | J Clin Med |
|---|---|
| Principais autores: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6912454/ https://ncbi.nlm.nih.gov/pubmed/31683785 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm8111814 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|